Anti-VEGF Cardiovascular Licensing Deal Terms at Phase 2: 2025 Benchmarks

The median upfront payment for an anti-VEGF cardiovascular licensing deal at Phase 2 is now $340M. Total deal values in this space routinely cross $1.25 billion and stretch past $3.5 billion. Royalty tiers run 8% to 18%. These are not speculative gene therapy numbers built on hope and optionality — these are anti-VEGF cardiovascular licensing deal terms at phase 2 reflecting Big Pharma's urgent, well-capitalized conviction that the next generation of VEGF-targeting therapeutics will redefine cardiovascular care. If you are negotiating, structuring, or evaluating one of these deals in 2025, this is the benchmark landscape you need to understand.

The thesis is straightforward: cardiovascular is no longer the risk-averse therapeutic area where pharma waits for Phase 3 readouts before writing checks. The combination of massive unmet need, validated biology (VEGF pathways are clinically proven, not theoretical), and looming patent cliffs on blockbuster cardiovascular franchises has created a seller's market for Phase 2 anti-VEGF assets. But the deal structures themselves tell a more nuanced story — one about how buyers are distributing risk, where milestone triggers actually sit, and why the royalty rate printed in a press release is almost never the number that matters.

The Phase 2 Anti-VEGF Cardiovascular Licensing Market Right Now

Let's ground this in data before we interpret it. The current anti-VEGF cardiovascular licensing deal terms at phase 2 cluster around a well-defined range, but the variance within that range reveals critical information about buyer strategy and asset quality.

Several things jump out immediately. The floor on upfronts is $200M — there is no bargain-bin entry into this space at Phase 2. The ceiling on total deal value at $3.5 billion signals that buyers are modeling peak sales projections north of $5 billion for the most compelling assets. And the royalty range of 8% to 18% is wide enough to be meaningful; the difference between 8% and 18% on a $3B peak-sales asset is roughly $300M in annual margin impact to the licensee. That is not a rounding error.

What the data actually says: The upfront-to-total-value ratio in anti-VEGF cardiovascular licensing deals sits around 14-16%. This is tighter than oncology (where upfronts can be 5-10% of total value) and reflects the cardiovascular buyer's preference for certainty over optionality. When you see a ratio below 10%, the buyer is hedging. When it exceeds 20%, the buyer is desperate.

The broader cardiovascular licensing landscape in 2025 is shaped by three forces. First, the patent cliff on established cardiovascular franchises — particularly in heart failure and atherosclerosis — has created genuine urgency among top-10 pharma companies. Second, the anti-VEGF mechanism, long validated in ophthalmology, is generating compelling cardiovascular data in areas like ischemic heart disease, peripheral arterial disease, and cardiac remodeling. Third, the number of clinical-stage anti-VEGF cardiovascular assets remains small. Supply is constrained. Demand is not. That imbalance explains why upfronts have escalated so dramatically. For deeper analysis on cardiovascular deal trends, see our Cardiovascular Deal Benchmarks.

What the Benchmark Data Reveals

Raw numbers are necessary but insufficient. What matters is the structure beneath the numbers — how upfronts, milestones, and royalties interact to distribute risk and incentive between licensor and licensee.

Upfront Payments: The Price of Entry

The $200M-$504M upfront range for anti-VEGF cardiovascular licensing deal terms at phase 2 represents the licensor's non-refundable risk premium. It compensates for years of preclinical and early clinical investment, and it prices the probability-adjusted value of a cardiovascular asset with Phase 2 data. At the median of $340M, the upfront is effectively a statement by the buyer: "We believe this asset has a greater-than-40% probability of reaching the market, and we are willing to pre-pay accordingly."

But the upfront is also a negotiating lever. In competitive processes — where multiple pharma companies are bidding — upfronts get pushed toward the high end of the range. In bilateral negotiations, they tend to settle closer to median. The difference between a $200M and a $504M upfront is not just asset quality; it is process quality. Biotechs that run structured competitive processes consistently extract 30-50% higher upfronts than those that negotiate with a single partner.

Total Deal Values: What Are You Really Buying?

Total deal values in the $1.25B-$3.5B range are composed primarily of clinical and regulatory milestones, with a smaller tranche of commercial milestones. The critical question is how those milestones are distributed. A deal with $3.5B in total value but $3B in commercial milestones that only trigger at $2B+ in annual net sales is fundamentally different from a deal with $3.5B in total value where $1.5B sits in clinical and regulatory milestones achievable within 4-5 years.

What the data actually says: In cardiovascular licensing deals, approximately 35-45% of total deal value sits in clinical/regulatory milestones, with 55-65% in commercial milestones. This is a more balanced split than oncology, where commercial milestones often represent 70%+ of total value. Cardiovascular buyers are more willing to pay for clinical progress, not just commercial outcomes.

Royalties: The Long Game

The 8% to 18% royalty range deserves careful unpacking. Single-digit royalties (8-10%) typically accompany deals where the licensee is taking on significant remaining development risk — larger Phase 3 programs, complex regulatory paths, or geographically broad rights. Double-digit royalties (14-18%) are reserved for assets with cleaner Phase 2 data, narrower remaining risk, or where the licensor retains co-promotion rights or profit-sharing in key markets.

The royalty rate is also a function of territory. Worldwide exclusive licenses in cardiovascular tend to carry royalties at the lower end of the range (the buyer is paying for global rights and assuming global risk). Deals carved by geography — ex-U.S., ex-China, or regional licenses — can push royalties higher because the licensor retains optionality. For custom benchmarking on your specific deal structure, use our Deal Calculator.

Deal Deconstruction: How the Biggest Anti-VEGF Cardiovascular Licensing Deals Were Structured

Let's move from benchmarks to real transactions. The following five deals represent the current comparable set for anti-VEGF cardiovascular licensing deal terms at phase 2. Each tells a different story about buyer motivation, seller leverage, and structural creativity.

Anthos Therapeutics → Novartis (2025): The Conviction Premium

The Anthos deal is the outlier that proves the rule. A $925M upfront — nearly three times the median for this space — represents the most aggressive move Novartis has made in cardiovascular licensing in years. Why did they pay this much?

Three factors converged. First, Anthos had Phase 2b data that was, by multiple accounts, near-pivotal quality. The dataset was large enough, the endpoints clean enough, and the safety signal benign enough that Novartis could model a streamlined Phase 3 with higher-than-average probability of success. Second, Novartis was not the only bidder. Anthos ran a competitive process that reportedly included at least two other top-10 pharma companies. Competitive tension drives upfronts — this is the single most reliable finding in biopharma deal analysis. Third, Novartis has a well-documented patent cliff in its cardiovascular franchise. Entresto's exclusivity runway is narrowing, and the company needs pipeline replenishment on a timeline measured in quarters, not decades.

The $3.1B total deal value, while substantial, results in an upfront-to-total ratio of nearly 30% — the highest in our comparable set by a wide margin. This ratio tells you Novartis was paying for certainty, not optionality. They wanted the asset, and they priced the deal to win it.

The milestone structure, at roughly $2.2B beyond the upfront, likely includes a Phase 3 initiation milestone (probably $200-300M), a first regulatory submission milestone ($300-400M), approval milestones across major markets ($500-700M combined), and commercial milestones tiered against net sales thresholds. The royalties, while not publicly disclosed in granular detail, are reported to be in the mid-to-high teens — consistent with the licensor's strong negotiating position.

What the data actually says: When the upfront exceeds 25% of total deal value, the buyer has essentially pre-paid for Phase 3 risk. This is rare and typically occurs only when the buyer has competitive intelligence suggesting the asset is near-pivotal and the seller has multiple bidders at the table.

Alnylam Pharmaceuticals → Roche (2024): The Platform Play

The Alnylam-Roche deal at $310M upfront / $2.2B total is the cleanest benchmark in our set. The upfront-to-total ratio of 14.1% sits precisely at the median for anti-VEGF cardiovascular licensing deals, and the structure reflects a well-balanced risk distribution between two sophisticated parties.

What makes this deal instructive is the platform dimension. Alnylam's RNAi technology applied to cardiovascular VEGF targets is not a single-asset play — it is a modality thesis. Roche was licensing both the specific clinical candidate and access to Alnylam's delivery technology in the cardiovascular space. This dual value (asset + platform) justifies the $310M upfront even though the clinical data was mid-Phase 2. Roche was paying a premium for the optionality embedded in the platform, not just the probability-adjusted NPV of one molecule.

The royalty structure in platform deals tends to be tiered differently than single-asset deals. Expect base royalties in the 10-14% range on the lead candidate, with lower royalties (6-10%) on follow-on candidates discovered using the platform, and potentially no royalties on candidates developed independently by the licensee using general knowledge gained from the collaboration. These nuances rarely make press releases but are critical in term sheet negotiations.

Shanghai Argo → Novartis (2024): The Geopolitical Discount

The Shanghai Argo deal — $185M upfront / $4.2B total — demonstrates how origin-of-asset affects deal economics in 2024-2025. The upfront-to-total ratio of 4.4% is the second-lowest in our comparable set. That gap between $185M upfront and $4.2B total is not explained by asset quality alone; it reflects a structural discount applied to China-origin cardiovascular assets.

This discount has three components: regulatory uncertainty (FDA's evolving posture on China-generated clinical data), IP concerns (enforceability of patents with Chinese priority dates), and manufacturing risk (supply chain dependencies on Chinese CMOs). Novartis mitigated these risks by pushing value into milestones — essentially saying, "We'll pay you $4.2B, but only as you de-risk the regulatory and manufacturing path."

For biotech founders with China-origin anti-VEGF cardiovascular assets, this deal sets a clear precedent: expect a 40-60% discount on upfront payments relative to U.S.- or European-origin assets at the same clinical stage. The total deal value can still be very large, but the upfront will be compressed. Plan your cash runway accordingly. For a full landscape view, visit our Cardiovascular Therapeutic Area Overview.

The Framework: The Cardiovascular Conviction Ratio

Here is the framework that, in our analysis, best explains the variation in anti-VEGF cardiovascular licensing deal terms at phase 2. We call it The Cardiovascular Conviction Ratio (CCR).

The CCR is calculated as:

CCR = Upfront Payment / (Total Deal Value × Estimated Probability of Approval)

For Phase 2 cardiovascular assets, assume a base probability of approval of approximately 30-35% (consistent with historical cardiovascular Phase 2-to-approval transition rates). The CCR tells you how much the buyer is willing to pre-pay per unit of risk-adjusted value.

Let's apply it to our comparable deals:

• Anthos → Novartis: CCR = $925M / ($3,100M × 0.35) = 0.85. This is an extraordinarily high CCR. Novartis assigned near-certain approval probability to this asset.
• Alnylam → Roche: CCR = $310M / ($2,200M × 0.30) = 0.47. A balanced CCR — Roche is paying a reasonable premium but retaining significant upside in milestones.
• Shanghai Argo → Novartis: CCR = $185M / ($4,200M × 0.25) = 0.18. The low CCR reflects both the milestone-heavy structure and the reduced probability estimate applied to China-origin assets.
• CSPC → AstraZeneca: CCR = $100M / ($2,020M × 0.25) = 0.20. Similar to Shanghai Argo — AstraZeneca is pricing in higher risk and deferring value to milestones.

The CCR gives BD teams and founders a single number to benchmark against. A CCR above 0.50 means the buyer has high conviction and the seller has strong leverage. A CCR below 0.25 means the deal is milestone-loaded and the seller should scrutinize the achievability of those milestones very carefully.

What the data actually says: The median CCR for anti-VEGF cardiovascular deals at Phase 2 sits around 0.40-0.50. If your term sheet implies a CCR below 0.25, you are likely leaving value on the table — or the buyer sees risk you haven't addressed. Either way, it demands a conversation.

Why Conventional Wisdom Is Wrong About Royalty Rates in Cardiovascular Licensing

Here is the contrarian take: royalty rates in cardiovascular licensing deals are the wrong number to optimize for.

Every biotech founder walks into a licensing negotiation focused on the royalty rate. "We want 15% royalties." "We need double-digit royalties." This is understandable — royalties are the most visible long-term economic term, and they feel like a proxy for how much the buyer values your asset. But in anti-VEGF cardiovascular deals, the royalty rate is far less important than the royalty tier thresholds and the net sales definition.

Consider two hypothetical deals, both with a headline royalty of 15%:

• Deal A: 15% royalty on net sales, where net sales are defined as gross sales minus returns, rebates, chargebacks, and distribution fees. In cardiovascular (where managed care rebates can consume 40-60% of gross-to-net), this 15% royalty on a $3B gross-sales asset translates to 15% × $1.5B = $225M annually.
• Deal B: 12% royalty on net sales, where net sales are defined as gross sales minus returns only (rebates carved out of the deduction). On the same $3B gross-sales asset, this translates to 12% × $2.7B = $324M annually.

Deal B has a lower headline royalty and pays the licensor $99M more per year. The net sales definition is doing all the work.

Similarly, royalty tier thresholds — the net sales levels at which the royalty rate steps up — are far more consequential than the base rate. A deal with 10% royalties on the first $1B of net sales and 16% above $1B is dramatically more valuable than a flat 14% on all sales if the asset reaches $3B in peak sales. The tiered deal pays $100M + $320M = $420M; the flat deal pays $420M. In this hypothetical they are identical, but shift the thresholds or the peak sales estimate and the outcomes diverge wildly.

The negotiation playbook is clear: spend less time arguing about the headline royalty rate and more time on net sales definitions, tier thresholds, royalty duration (does it expire on patent expiry or on a fixed term?), and royalty offsets for generic entry. These are the terms that determine whether your 15% royalty is actually worth 15%.

The Negotiation Playbook for Anti-VEGF Cardiovascular Licensing Deals

For anyone sitting across the table on an anti-VEGF cardiovascular licensing deal at Phase 2, here are the specific tactical recommendations grounded in our benchmark data.

1. Before You Accept the Term Sheet, Calculate the CCR

Use the Cardiovascular Conviction Ratio framework above. If your CCR is below 0.30, the buyer's term sheet is milestone-heavy and you need to pressure-test every milestone for achievability. Ask: "What is the probability-weighted present value of these milestones?" If the buyer can't answer that question with a specific number, the milestones are aspirational, not real.

2. Push Back on Milestone Trigger Definitions

In cardiovascular deals, the difference between "first patient dosed in Phase 3" and "Phase 3 fully enrolled" as a milestone trigger can represent 18-24 months of timing and tens of millions in NPV. Always push for earlier milestone triggers — first patient dosed, IND acceptance, end-of-Phase-2 meeting with FDA. These are events within your control or at least within a shorter timeframe.

3. Demand a Competitive Process or Simulate One

The Anthos deal proves it: a competitive process drove the upfront from what would likely have been $400-500M in a bilateral negotiation to $925M. If you cannot run a genuine competitive process (because your asset is too early, too niche, or you lack the relationships), simulate competitive tension by engaging business development teams at 3-5 pharma companies simultaneously and ensuring each knows the others are at the table. This is not gamesmanship; it is fiduciary responsibility.

4. The Red Flag in This Structure Is Excessive Commercial Milestones

If more than 65% of total deal value sits in commercial milestones tied to net sales thresholds above $2B, the deal is structured to benefit the buyer disproportionately. Most cardiovascular drugs never reach $2B in annual net sales. The $3B-$5B blockbuster is the exception, not the rule. Push for a higher proportion of value in clinical and regulatory milestones that you can actually influence and that trigger within 3-5 years of deal signing.

5. Negotiate the Royalty Floor, Not Just the Rate

Insist on a minimum royalty provision — a floor below which royalties cannot be reduced even in the event of generic entry, co-commercialization adjustments, or third-party IP offsets. A 15% royalty that gets reduced to 7% because of a freedom-to-operate payment to a third-party patent holder is not a 15% royalty. It is a 7% royalty with good marketing.

6. Cite the Alnylam-Roche Precedent for Balanced Structures

If you are a biotech founder negotiating with a large pharma, the Alnylam-Roche deal ($310M upfront / $2.2B total / ~14% upfront ratio) is the single best precedent to cite for a "fair" deal. It is recent, well-publicized, and represents a balanced risk-reward split between two parties with roughly equal negotiating sophistication. Use it as your anchor.

For Biotech Founders

If you are a founder holding a Phase 2 anti-VEGF cardiovascular asset, here is what your asset is worth and how to think about the licensing decision.

Your asset is worth $200M-$504M in upfront value. That is the range. Where you land within it depends on four variables: quality of Phase 2 data (effect size, safety, biomarker evidence), competitive process dynamics, buyer strategic urgency, and your own alternatives (can you fund Phase 3 independently?). If you have all four working in your favor, you should be targeting the upper quartile. If you are missing two or more, the lower quartile is realistic.

The licensing decision is a financing decision. Out-licensing at Phase 2 means selling 85-92% of your asset's future value (since you retain only royalties) in exchange for certainty. If your board can fund a $150M-$300M Phase 3 cardiovascular trial independently or through a public offering, retaining the asset may generate more total value. But "may" is doing a lot of work in that sentence. Phase 3 cardiovascular trials fail 50-60% of the time. The risk-adjusted math often favors licensing at Phase 2, especially for companies without deep Phase 3 execution experience in cardiovascular.

Do not optimize for headline total deal value. A $4B total deal value with a $150M upfront and $3.85B in milestones is not meaningfully different from a $2.5B total deal value with a $400M upfront and $2.1B in milestones — the second deal puts more cash on your balance sheet when you need it and has more achievable milestones. Focus on upfront, near-term milestones (within 3 years), and royalty floor. Everything else is optionality that may never vest.

For a personalized valuation of your asset against these benchmarks, request a Full Deal Report.

For BD Professionals

If you are a VP or Director of BD at a pharma company evaluating an in-license of a Phase 2 anti-VEGF cardiovascular asset, here is what you need to know for deal committee defensibility.

The benchmark defense is strong at $340M upfront. You can cite our data and the comparable deal set to justify an upfront in the $200M-$504M range. The median of $340M is defensible in any deal committee presentation. If you are going above $504M, you need an Anthos-level rationale: near-pivotal data, competitive process, and strategic urgency tied to your own pipeline gaps.

Structure the milestone schedule to reflect your internal development plan. Do not agree to milestone triggers that depend on the seller's actions post-deal. Every milestone should be tied to an event you control — IND filing, Phase 3 initiation, regulatory submission. If the seller insists on milestones tied to their manufacturing scale-up or technology transfer timelines, push back. Your deal committee will flag this as an uncontrolled liability.

Royalty negotiations are where you create margin. The headline royalty rate is what gets reported in press releases. The effective royalty rate — after net sales adjustments, tiering, offsets, and duration provisions — is what hits your P&L. A deal at 14% headline royalties with a broad net sales definition and no floor is materially better for the buyer than a deal at 11% headline royalties with a narrow net sales definition and a 9% floor. Model both scenarios before you present to the deal committee.

Prepare for the "why not build?" question. Every deal committee will ask whether it is cheaper to develop your own anti-VEGF cardiovascular program internally. The answer, in 2025, is almost certainly no — not because internal programs are expensive (they are) but because they are slow. Building a Phase 2-ready anti-VEGF cardiovascular asset from scratch takes 5-7 years. Licensing one takes 6 months. If your patent cliff is in 2028 or 2029, speed-to-market is the dominant variable, and it overwhelms any cost-of-capital argument.

What Comes Next

Three predictions for anti-VEGF cardiovascular licensing deal terms at Phase 2 over the next 18 months:

1. Median upfronts will breach $400M by mid-2026. The supply of Phase 2 anti-VEGF cardiovascular assets is not growing fast enough to meet demand from pharma companies facing patent cliffs. Scarcity pricing will push upfronts higher. The $340M median we see today is an inflection point, not a ceiling.

2. Novartis will continue to dominate deal volume. Three of the five comparable deals in our dataset involve Novartis as the buyer. This is not coincidence — it reflects a deliberate, well-funded cardiovascular pipeline strategy driven by Entresto lifecycle management and the need for next-generation heart failure and atherosclerosis assets. Expect Novartis to announce at least one additional cardiovascular licensing deal by Q2 2026.

3. Royalty structures will shift toward sales-based tiers with escalators. The flat royalty is dying. In its place, expect tiered royalty structures with escalators tied to specific net sales thresholds — 10% on the first $1B, 14% on $1-3B, 18% above $3B. This structure aligns incentives and is gaining acceptance among both buyers and sellers. If your current term sheet has a flat royalty, you are negotiating with a 2020 playbook.

The bottom line: Phase 2 is now the value-maximizing licensing window for anti-VEGF cardiovascular assets, and the deal terms being set in 2024-2025 will define the benchmark landscape for the next half-decade. Whether you are selling or buying, the data is your leverage. Use it.